Company profile for PINOTBIO

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

PINOTBIO is a biotech that develops new treatments for patients who are resistant to existing treatments based on innovative new drug modalities such as Antibody Drug Conjugates (ADCs). Based on its strong R&D capabilities, it has independently built PINOT-ADC™, a next-generation ADC platform, and is concentrating on researching new anti-cancer ADC drugs with various partners. In addition, clinical development and commercial...
PINOTBIO is a biotech that develops new treatments for patients who are resistant to existing treatments based on innovative new drug modalities such as Antibody Drug Conjugates (ADCs). Based on its strong R&D capabilities, it has independently built PINOT-ADC™, a next-generation ADC platform, and is concentrating on researching new anti-cancer ADC drugs with various partners. In addition, clinical development and commercialization of NTX-301, a target anti-cancer drug for blood cancer/solid cancer, and NTX-101, a glaucoma treatment, are in progress.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
South Korea
Address
Address
8th floor, 156, Gwanggyo-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do
Telephone
Telephone
+82 3180641304
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty